Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

August 30, 2027

Conditions
Ureter CancerRenal Pelvic CarcinomaAdvanced Urothelial Carcinoma
Interventions
COMBINATION_PRODUCT

Immunotherapy+radiotherapy

"Adjuvant Immunotherapy: Immunotherapy drug of choice is tirilizumab, which has received national recommendations in metastatic uroepithelial cancer. Tirelizumab 200mg Q3w; the duration of immunotherapy is recommended for at least 1 year.~Adjuvant radiotherapy can be given concurrently or sequentially with adjuvant immunotherapy; it is recommended that radiotherapy can be started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT), daily image-guided radiotherapy (Daily IGRT) techniques are used."

OTHER

surveillance alone

Patients recieve surveillance alone without any adjuvant interventions until any disease progression endpoints occur.

Trial Locations (2)

Unknown

RECRUITING

Departmeng of Urology, Peking University First Hospital, Beijing

RECRUITING

Department of Radiotherapy Oncology, Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER